Detail akcie Tempest Thrptc Rg online

Business Summary: Tempest Therapeutics, Inc. is a clinical-stage biotechnology company moving towards late-stage development with a portfolio of targeted and immune-mediated product candidates with the potential to be first-in-class to treat a range of cancers. Its programs range from early research to the lead program, amezalpat, a pivotal study in first-line hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, is a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 (PGE2), a pathway implicated in multiple cancers. Its development strategy for TPST-1495 includes evaluation in familial adenomatous polyposis (FAP), a rare genetic disorder that increases the risk of gastrointestinal cancers. Its pipeline also includes TPST-2003, TPST-2206, TPST-3003, and TPST-3206. TPST-2003 is a new dual-targeting CD19/BCMA CAR-T asset. TPST-2206 is a dual-targeting CD70/CD70 CAR-T for renal cell carcinoma. TPST-3206 is an allogeneic dual-targeting CD70/CD70.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Tempest Therapeutics Inc revenues was not reported. Net loss decreased 21% to $22.2M. Lower net loss reflects Research and development - Balancing decrease of 40% to $7.5M (expense), Interest Expense decrease of 81% to $207K (expense), Stock-based Compensation in SGA decrease of 32% to $1.6M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$15.46 to -$6.02.